In an open letter to customers, which was obtained by ChinaBio®, Dr. Ge Li, Chairman and CEO of WuXi AppTec, said “short-term financial concerns” were the reason its merger with Charles River Labs was not completed. Dr. Li expressed regret that the failure of the merger would slow WuXi’s evolution into a company with a broader set of CRO capabilities. More details...

Stock Symbols: (NYSE: WX) (NYSE: CRL)